Nabil M Ahmed

Dr. Nabil M Ahmed is a Professor at Baylor College of Medicine, specializing in Pediatrics-Hem-Onc Cell & Gene and affiliated with the Dan L Duncan Comprehensive Cancer Center. His research focuses on adoptive immunotherapy using gene-modified T cells to target brain tumors like glioblastoma and osteosarcoma, with clinical trials approved by FDA/IRB/RAC/IBC. He leads 3 active clinical trials and has pioneered studies on tumor-specific T cell efficacy, including targeting tumor stem cells and improving T cell migration to brain tumors. His work integrates cell and gene therapy with translational research, emphasizing CAR T-cell engineering and combination therapies. Professional interests include bone marrow transplantation and cell therapy for malignant solid tumors.

Research highlights include demonstrating tumor niche modulation by T cells and developing delivery systems for CAR T cells to brain tumors. Key contributions span preclinical and clinical studies, including trials of HER2-specific CAR T cells in sarcoma and glioblastoma. Affiliations include Texas Children's Hospital clinics and laboratories at the Baylor College of Medicine campus. His publications address CAR T-cell design, oncolytic virus therapies, and long-term safety of immune effector therapies.